Company research
SeaStar Medical Holding Corp
CIK 1831868Updated Sep 24, 2026
Name history
LMF Acquisition Opportunities Inc · through Oct 27, 2022
ICU price & chart
Loading TradingView…
NASDAQ:ICU on TradingView ↗About the company
We are a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. Our Selective Cytopheretic Device (“SCD”) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. It has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases.
In the news
SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026 ↗
Seeking Alpha
Seastar medical targets NEUTRALIZE-AKI enrollment completion around year-end or Q1 2027 as QUELIMMUNE adoption reaches 20 hospitals ↗
SeaStar Medical Holding Corporation (ICU) Q2 2026 Earnings Call Transcript ↗
Seastar Medical targets about $2M 2026 QUELIMMUNE revenue while aiming to finish NEUTRALIZE-AKI enrollment by end of 2026 ↗
Recent filings
Show 5 more recent filings
4 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
424B3 filing
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 14,158,000Source | 4,658,000Source | 3,647,000Source | 4,767,000Source |
| Current assets: | ||||
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 237,000Source | 112,000Source | — | — |
| Inventory, NetUSD | 66,000Source | 0Source | — | — |
| Assets, CurrentUSD | 13,580,000Source | 3,766,000Source | 2,206,000Source | 3,036,000Source |
| Other Assets, NoncurrentUSD | 578,000Source | — | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 3,742,000Source | 6,841,000Source | 27,022,000Source | 13,002,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | — | — |
| Common Stock, Value, IssuedUSD | 4,000Source | 2,000Source | 1,000Source | — |
| Additional Paid in CapitalUSD | 162,126,000Source | 137,379,000Source | 72,222,000Source | 91,089,000Source |
| Retained Earnings (Accumulated Deficit)USD | -151,714,000Source | -139,564,000Source | -95,598,000Source | -99,325,000Source |
| Stockholders' Equity Attributable to ParentUSD | 10,416,000Source | -2,183,000Source | -23,375,000Source | -8,235,000Source |
| Liabilities and EquityUSD | 14,158,000Source | 4,658,000Source | 3,647,000Source | 4,767,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 3,742,000Source | 6,841,000Source | 21,277,000Source | 5,350,000Source |
| Accounts Payable, CurrentUSD | 948,000Source | 3,046,000Source | 3,022,000Source | 1,927,000Source |
| Additional Financial Items | ||||
| Accounts Receivable, after Allowance for Credit LossUSD | 237,000Source | — | — | — |
| Accrued Liabilities, CurrentUSD | 2,268,000Source | 3,188,000Source | 1,792,000Source | 2,245,000Source |
| Long-term Debt, Current MaturitiesUSD | — | 574,000Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | -24,830,000Source | — | -23,013,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 624,000Source | 887,000Source | — | — |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 125,000Source | 112,000Source | — | — |
| Increase (Decrease) in InventoriesUSD | 66,000Source | — | — | 0Source |
| Increase (Decrease) in Accounts PayableUSD | -2,098,000Source | -1,281,000Source | — | 1,548,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -13,599,000Source | -16,007,000Source | — | -7,794,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 23,760,000Source | 17,650,000Source | — | 7,331,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 10,161,000Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | 1,819,000Source | 725,000Source | 47,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | 553,000Source | — | 6,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 624,000Source | 887,000Source | — | 1,311,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 18,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | 0Source | — | — |
| General and Administrative ExpenseUSD | 5,838,000Source | 8,872,000Source | — | 6,600,000Source |
| Income Tax Expense (Benefit)USD | 3,000Source | 3,000Source | — | 1,000Source |
| InterestExpenseNonoperatingUSD | 31,000Source | — | — | — |
| Investment Income, InterestUSD | 325,000Source | 101,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -12,150,000Source | -24,830,000Source | — | -23,013,000Source |
| Nonoperating Income (Expense)USD | 28,000Source | — | — | — |
| Operating ExpensesUSD | 13,356,000Source | 17,977,000Source | — | 11,609,000Source |
| Operating Lease, ExpenseUSD | 75,000Source | 43,000Source | — | 32,000Source |
| Other Nonoperating Income (Expense)USD | — | -6,985,000Source | — | -11,403,000Source |
| Proceeds from Issuance of Common StockUSD | 16,126,000Source | 17,441,000Source | — | — |
| Proceeds from Issuance of Long-term DebtUSD | — | 1,087,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 1,234,000Source | 135,000Source | — | — |
| Cost of RevenueUSD | 53,000Source | 0Source | — | — |
| Operating Income (Loss)USD | -12,175,000Source | -17,842,000Source | -14,210,000Source | -11,609,000Source |
| Other Nonoperating Income (Expense)USD | — | -6,985,000Source | -12,022,000Source | -11,403,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -12,147,000Source | -24,827,000Source | -26,232,000Source | -23,012,000Source |
| Income Tax Expense (Benefit)USD | 3,000Source | 3,000Source | 0Source | 1,000Source |
| Net Income (Loss) Attributable to ParentUSD | -12,150,000Source | -24,830,000Source | -26,232,000Source | -23,013,000Source |
| Earnings Per Share, BasicUSD per share | -5.86Source | -6.63Source | -1.21Source | -2.8Source |
| Earnings Per Share, DilutedUSD per share | — | -6.63Source | -1.21Source | -2.8Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 2,073,087Source | 3,743,554Source | 21,670,330Source | 8,211,256Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | 3,743,554Source | 21,670,330Source | 8,211,256Source |
| Interest Expense (non-operating)USD | 31,000Source | — | — | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | — | 3,000Source | 4,000Source | 1,000Source |
| General and Administrative ExpenseUSD | 5,838,000Source | 8,872,000Source | 8,237,000Source | 6,600,000Source |
| Gross ProfitUSD | 1,181,000Source | 135,000Source | — | — |
| Interest ExpenseUSD | — | 244,000Source | 1,081,000Source | 630,000Source |
| Investment Income, InterestUSD | 325,000Source | 101,000Source | — | — |
| Nonoperating Income (Expense)USD | 28,000Source | — | — | — |
| Operating ExpensesUSD | 13,356,000Source | 17,977,000Source | 14,210,000Source | 11,609,000Source |
| Operating Lease, ExpenseUSD | 75,000Source | 43,000Source | 32,000Source | 32,000Source |
| Other IncomeUSD | — | 0Source | 151,000Source | — |
| Research and Development ExpenseUSD | 7,518,000Source | 9,105,000Source | 5,973,000Source | 2,819,000Source |
Offerings
Registration 333-295384
Registration 333-289447
Registration 333-288065
- Gross proceeds
- 4000000.55
- Net proceeds
- 3680000.51
- Deal price
- 0.65
- Shares
- 6153847
- Offering price
- $0.65
Registration 333-287403
Filing attachments
icu-ex99_1.htm · 8-K · 2025-09-24
EX-99.1 2 icu-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury Independent DSMB reports zero device-related safety issues Supports potential clinical benefit Trial sample size re-estimated to strengthen statistical power DENVER, CO (September 24, 2025) - SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments fo…
Read attachment ↗icu-ex99_1.htm · 8-K/A · 2025-08-14
EX-99.1 2 icu-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates Business highlights include: • Adult NEUTRALIZE-AKI trial enrolls 31 new patients, now over 60% enrolled • Three new top-rated children’s hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI) • Positive survival results reported from QUELIMMUNE SAVE Surveillance Registry • Webcast call today at 4:30 p.m. Easte…
Read attachment ↗icu-ex99_1.htm · 8-K · 2025-08-13
EX-99.1 2 icu-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates Business highlights include: • Adult NEUTRALIZE-AKI trial enrolls 31 new patients, now over 60% enrolled • Three new top-rated children’s hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI) • Positive survival results reported from QUELIMMUNE SAVE Surveillance Registry • Webcast call today at 4:30 p.m. Easte…
Read attachment ↗icu-ex4_1.htm · 8-K · 2025-08-01
EX-4.1 2 icu-ex4_1.htm EX-4.1 EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO A…
Read attachment ↗icu-ex4_2.htm · 8-K · 2025-08-01
EX-4.2 3 icu-ex4_2.htm EX-4.2 EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO A…
Read attachment ↗icu-ex99_1.htm · 8-K · 2025-08-01
EX-99.1 6 icu-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules DENVER, July 31, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, today announced it has entered into a definitive agreement for the issuance and sale of an…
Read attachment ↗